Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This emerging Bitcoin infrastructure company is building a vertically integrated model (click to learn more) Laser Photonics Announces Strategic Milestone on Advanced Laser Shield Anti Drone System (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Camurus AB (PK) CAMRF

Healthcare Biotechnology
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (PINL:CAMRF)

The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence

PR Newswire May 3, 2021

Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence

PR Newswire March 26, 2021

Positive Results From Phase 2 Study of Once-weekly FluidCrystal® Formulation of Setmelanotide in Healthy Volunteers With Obesity

PR Newswire June 24, 2020

Camurus Raises Full Year 2020 Revenue Guidance

PR Newswire June 23, 2020

Camurus Announces Submission of Request for Final Approval of Brixadi(TM) for the Treatment of Opioid Use Disorder in the US

PR Newswire June 1, 2020

Camurus' Interim Report January-March 2020

PR Newswire May 7, 2020

Camurus Announces Strong First Quarter Demand for Buvidal®

PR Newswire April 2, 2020

Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan

PR Newswire July 16, 2019

Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly

PR Newswire June 20, 2019
View More News ››

Opinion & Analysis (PINL:CAMRF)

No current opinion is available.
View More Opinion ››

Bullboard Posts (PINL:CAMRF)

Be the first to post on this bullboard.

US Energy Corp

US Energy Corp

U.S. Energy Corp., an independent energy company, focuses on the acquisition, exploration, and development of industrial gas, ...
View More »

Podcasts